Sagimet Biosciences (SGMT) Cash from Investing Activities (2022 - 2026)

Sagimet Biosciences' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $10.2 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 199.33% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $11.4 million (up 118.54% YoY), while the FY2025 annual figure was $4.6 million, up 107.39% from the prior year.
• Cash from Investing Activities was $10.2 million for Q1 2026 at Sagimet Biosciences, down from $14.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $19.4 million in Q1 2023 to a low of -$75.2 million in Q2 2024.
• Historically, Cash from Investing Activities has averaged -$1.8 million across 5 years, with a median of $3.7 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Cash from Investing Activities plunged 687.16% in 2024, then surged 199.33% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at $5.4 million in 2022, then sank by 460.93% to -$19.6 million in 2023, then soared by 150.2% to $9.8 million in 2024, then surged by 45.77% to $14.4 million in 2025, then fell by 28.85% to $10.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $10.2 million (Q1 2026), $14.4 million (Q4 2025), and $75000.0 (Q3 2025), per Business Quant data.